Jefferies initiates Abivax stock coverage with buy rating on UC drug

drug approval expired 60% Health

Jefferies has initiated coverage of Abivax stock with a buy rating, expressing optimism about the company's ulcerative colitis (UC) drug candidate. The initiation signals analyst confidence in Abivax's pipeline and commercial prospects.

🇫🇷 Location: FR — Sources: 1 — First seen: — Last seen:
Abivax Jefferies buy rating ulcerative colitis biotech

Contributing Articles